利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.035 秒)

    Oligosaccharide aromatic glycoside and sulfate thereof
    1.
    发明授权
    Oligosaccharide aromatic glycoside and sulfate thereof 失效
    寡糖芳香糖苷及其硫酸盐

    公开(公告)号：US5498602A

    公开(公告)日：1996-03-12

    申请号：US944077

    申请日：1992-09-11

    申请人： Tadao Shoji ,  Nahoko Takahashi ,  Naoya Ikushima ,  Toshiyuki Uryu ,  Takashi Yoshida ,  Naoki Yamamoto ,  Hideki Nakashima ,  Kaname Katsuraya ,  Koichiro Adachi ,  Fusayo Kataoka

    发明人： Tadao Shoji ,  Nahoko Takahashi ,  Naoya Ikushima ,  Toshiyuki Uryu ,  Takashi Yoshida ,  Naoki Yamamoto ,  Hideki Nakashima ,  Kaname Katsuraya ,  Koichiro Adachi ,  Fusayo Kataoka

    IPC分类号： A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61P31/12 ,  A61P31/18 ,  C07H15/203 ,  C08B37/00 ,  C07G3/00 ,  C07H11/00

    CPC分类号： C07H15/203 ,  C08B37/006

    摘要： Oligosaccharide aromatic glycoside sulfates and physiologically acceptable salts thereof, are disclosed. Further, antiviral agents having these sulfate compounds as the active components, and particularly an antiviral agent, wherein the virus is one which causes AIDS (Acquired Immune Deficiency Syndrome), are disclosed. The active components or the glycoside sulfates, and the salts thereof, are characterized by an oligosaccharide aromatic glycoside sulfate in which the hydrogen of the position-1 hydroxyl group of the terminal sugar of an oligosaccharide is substituted with a specified formula having an alkyl group consisting of 1 to 18 carbons, an oxygen or no oxygen, and an allylene group. The number of constituent monosaccharides in the oligosaccharide portion is preferably within a range of 2 to 20. Further, 10% or more of the remaining hydroxyl groups of the sugar subunits are subjected to sulfated esterification. In addition the antiviral agent exhibits low toxicity and is useful in the treatment of AIDS. Furthermore, an oligosaccharide is also disclosed as described above with the exception that it is the hydrogen atom of the position 1 hydrogen group at the terminal sugar residue which is substituted with the specified formula, also described above. However, in addition the remaining hydroxyl groups of the sugar portion of this oligosaccharide are protected by acyl groups or are present in an unprotected form. Also disclosed is a method for the production of an oligosaccharide aromatic glycoside sulfate synthesized by sulfation using a sulfating agent.

    摘要翻译： 公开了寡糖芳香糖苷硫酸盐及其生理上可接受的盐。 此外，公开了具有这些硫酸盐化合物作为活性成分的抗病毒剂，特别是其中病毒是引起AIDS（获得性免疫缺陷综合征）的抗病毒剂。 活性成分或糖苷硫酸盐及其盐的特征在于寡糖芳香糖苷硫酸盐，其中寡糖末端糖的位置1羟基的氢被具有烷基的特定式所取代， 1至18个碳，氧或无氧，以及烯丙基。 寡糖部分中的构成单糖的数量优选在2〜20的范围内。此外，将糖亚基的剩余羟基的10％以上进行硫酸化酯化。 此外，抗病毒剂的毒性低，可用于治疗艾滋病。 此外，还公开了如上所述的寡糖，不同之处在于它是上述也被指定式取代的末端糖残基上的1位氢原子的氢原子。 然而，此外，该寡糖的糖部分的剩余羟基由酰基保护或以未保护的形式存在。 还公开了通过使用硫酸化剂硫酸化合成的寡糖芳香族糖苷硫酸盐的制造方法。

    Sulfated tocopheryl oligosaccharides and antiviral agents including the same as active ingredients
    2.
    发明授权
    Sulfated tocopheryl oligosaccharides and antiviral agents including the same as active ingredients 失效
    硫酸化生育酚低聚糖和包括与活性成分相同的抗病毒剂

    公开(公告)号：US5280111A

    公开(公告)日：1994-01-18

    申请号：US856710

    申请日：1992-03-24

    申请人： Tadao Shoji ,  Naoya Ikushima ,  Kaname Katsuraya ,  Nahoko Takahashi ,  Fusayo Kobayashi ,  Toshiyuki Uryu ,  Takashi Yoshida ,  Naoki Yamamoto ,  Hideki Nakashima

    发明人： Tadao Shoji ,  Naoya Ikushima ,  Kaname Katsuraya ,  Nahoko Takahashi ,  Fusayo Kobayashi ,  Toshiyuki Uryu ,  Takashi Yoshida ,  Naoki Yamamoto ,  Hideki Nakashima

    IPC分类号： A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61P31/12 ,  A61P31/18 ,  C07H17/065 ,  C07H15/20 ,  A61K31/72 ,  C07H11/00 ,  C07H13/02 ,  C07H17/04

    CPC分类号： C07H17/065 ,  A61K31/70

    摘要： The present invention relates to novel tocopheryl oligosaccharides, acylated tocopheryl oligosaccharides, sulfated tocopheryl oligosaccharides, and antiviral agents including the sulfated tocopheryl oligosaccharides as active ingredients. In the tocopheryl oligosaccharide, the hydrogen atom of the hydroxy group at the 1-position in the terminal sugar moiety of an oligosaccharide which consists of 3.about.20 of identical or different repeating monosaccharide units selected from the group consisting of glucose, galactose, mannose, talose, idose, altrose, allose, glucose, xylose, arabinose, rhamnose, fucose, and fructose, which are glycoside-linked, is substituted by a tocopherol group. In the acylated tocopheryl oligosaccharides, each of any hydroxy group of the sugar moiety, other than the hydroxy group at the 1-position in the terminal sugar moiety of the oligosaccharide described above, is protected by an acyl group. The antiviral agents including the sulfated tocopheryl oligosaccharides or the biologically acceptable salt of the same as active ingredients have low toxicities and exhibit improved antiviral action, especially against the Human Immunodeficiency Virus.

    摘要翻译： 本发明涉及新的生育酚低聚糖，酰化生育酚低聚糖，硫酸生育酚寡糖，以及包含硫酸生育酚寡糖作为活性成分的抗病毒剂。 在生育酚低聚糖中，低聚糖的末端糖部分的1位的羟基的氢原子由3〜20个相同或不同的重复单糖单元组成，所述重复单糖单元选自葡萄糖，半乳糖，甘露糖， 与糖生成酚基取代的与糖苷连接的谷氨酸，阿糖，阿卓糖，阿洛糖，葡萄糖，木糖，阿拉伯糖，鼠李糖，岩藻糖和果糖。 在酰化的生育酚低聚糖中，除了上述寡糖的末端糖部分的1位以外的除了羟基以外的糖部分的任何羟基都被酰基保护。 包括硫酸生育酚寡糖或与生物活性成分相同的生物学上可接受的盐的抗病毒剂具有低毒性，并且表现出改善的抗病毒作用，特别是针对人类免疫缺陷病毒。

    Alkylated oligosaccharides and acetyl derivatives of the same
    3.
    发明授权
    Alkylated oligosaccharides and acetyl derivatives of the same 失效
    烷基化低聚糖及其乙酰衍生物

    公开(公告)号：US5268461A

    公开(公告)日：1993-12-07

    申请号：US834305

    申请日：1992-02-25

    申请人： Tadao Shoji ,  Nahoko Takahashi ,  Koichiro Adachi ,  Naoya Ikushima ,  Kaname Katsuraya ,  Toshiyuki Uryu ,  Takashi Yoshida

    发明人： Tadao Shoji ,  Nahoko Takahashi ,  Koichiro Adachi ,  Naoya Ikushima ,  Kaname Katsuraya ,  Toshiyuki Uryu ,  Takashi Yoshida

    IPC分类号： C07H3/06 ,  C07H15/04 ,  C07H13/06

    CPC分类号： C07H15/04 ,  C07H3/06

    摘要： An alkylated oligosaccharide and the acetyl derivative of the same, both useful as the raw material for producing lowly toxic surfactants or medicines. The alkylated oligosaccharide is prepared by substituting with an alkyl group having a linear or branched chain the hydrogen atom of the hydroxy group at the 1-position of a terminal sugar moiety of an oligosaccharide in which glucose moieties are .beta.(1.fwdarw.3)-glucoside-linked, or of an oligosaccharide in which galactose is .beta.(1.fwdarw.4)-glycoside-linked at the 4-position in the galactose moiety of lactose and in which galactose moieties are .beta.(1.fwdarw.4)-glycoside-linked in succession to the newly formed terminal galactose moieties. The invention also includes an acetyl derivative of the oligosaccharide, wherein the hydroxy groups excluding the 2-positional hydroxy group adjacent to the alkyl-ether-linking position in the terminal sugar moiety are acetylated, and a mixture thereof. In addition, an acetylated oligosaccharide is allowed to react with an alcohol using a heteropolyacid as the reacting agent.

    摘要翻译： PCT No.PCT / JP91 / 00867 Sec。 371日期：1992年2月25日 102（e）1992年2月25日PCT PCT 1991年6月27日PCT公布。 出版物WO92 / 0031020 日本1992年1月9日。烷基化低聚糖及其乙酰衍生物，均可用作生产低毒性表面活性剂或药物的原料。 烷基化的寡糖通过用直链或支链的烷基取代，其中葡萄糖部分为β（1-> 3） - 寡糖的寡糖的末端糖部分的1-位羟基的氢原子， 葡萄糖苷连接的寡糖或寡聚糖，其中半乳糖是在乳糖的半乳糖部分的4-位上是β（1-> 4） - 糖苷连接的，其中半乳糖部分是β（1-> 4） - 糖苷 - 连接到新形成的末端半乳糖部分。 本发明还包括寡糖的乙酰衍生物，其中不包括与末端糖部分中的烷基 - 醚连接位置相邻的2-位羟基的羟基被乙酰化，以及它们的混合物。 此外，使用杂多酸作为反应剂，使乙酰化寡糖与醇反应。

    Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient
    4.
    发明授权
    Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient 失效
    硫酸低聚糖苷酰化物和含有与活性成分相同的抗病毒剂

    公开(公告)号：US5459257A

    公开(公告)日：1995-10-17

    申请号：US179623

    申请日：1994-01-07

    申请人： Tadao Shoji ,  Akira Kasai ,  Osamu Misumi ,  Naoya Ikushima ,  Naoki Yamamoto ,  Hideki Nakashima ,  Kazuhiko Inazawa ,  Nahoko Takahashi

    发明人： Tadao Shoji ,  Akira Kasai ,  Osamu Misumi ,  Naoya Ikushima ,  Naoki Yamamoto ,  Hideki Nakashima ,  Kazuhiko Inazawa ,  Nahoko Takahashi

    IPC分类号： C07H15/04 ,  C07H15/203 ,  C07H17/065 ,  C07H13/12 ,  C07H11/00

    CPC分类号： C07H15/203 ,  C07H15/04 ,  C07H17/065

    摘要： A sulfated oligoglycoside acylate comprising monosaccharides of a single or two kinds as the constituents, wherein the hydrogen in the hydroxyl group at the 1-position of a reducing end sugar of the oligosaccharide formed via the glycoside bond of these monosaccharides has been substituted with an aglycon selected from a group consisting of alkyl groups, aromatic alkyl groups, aromatic alkoxy groups and tocopheryl groups; from 12 to 80% of the residual hydroxyl groups have been acylated with an acyl group selected from a group consisting of aliphatic acyl groups and aromatic acyl groups; and 88 to 20% thereof have been sulfated; or a physiologically acceptable salt thereof provided that compounds wherein the aglycon is an alkyl group and the acyl group is an aliphatic acyl group are excluded is disclosed. Further, an antiviral agent, which exerts a long-lasting antiviral action particularly on HIV, containing said compound as an active ingredient is disclosed.

    摘要翻译： 一种包含单一或两种单糖作为组分的硫酸化寡糖苷酰化物，其中通过这些单糖的糖苷键形成的寡糖的还原性末端糖在1位羟基中的氢被aglycon取代 选自烷基，芳族烷基，芳族烷氧基和生育酚基; 残余羟基的12至80％已经用选自脂族酰基和芳族酰基的酰基酰化; 88％〜20％已被硫酸化; 或其生理学上可接受的盐，其中排除了糖苷配基是烷基和酰基是脂族酰基的化合物。 此外，公开了以含有所述化合物作为有效成分的对HIV特别施加长效抗病毒作用的抗病毒剂。

    Piperidine derivative and pharmaceutical composition containing the same
    5.
    发明授权
    Piperidine derivative and pharmaceutical composition containing the same 失效
    哌啶衍生物和含有其的药物组合物

    公开(公告)号：US5179095A

    公开(公告)日：1993-01-12

    申请号：US798963

    申请日：1991-11-26

    申请人： Hitoshi Oinuma ,  Motosuke Yamanaka ,  Kazutoshi Miyake ,  Tomonori Hoshiko ,  Norio Minami ,  Tadao Shoji ,  Yoshiharu Daiku ,  Kohei Sawada ,  Kenichi Nomoto

    发明人： Hitoshi Oinuma ,  Motosuke Yamanaka ,  Kazutoshi Miyake ,  Tomonori Hoshiko ,  Norio Minami ,  Tadao Shoji ,  Yoshiharu Daiku ,  Kohei Sawada ,  Kenichi Nomoto

    IPC分类号： C07D211/28 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D417/04 ,  C07D471/04 ,  C07D473/10

    CPC分类号： C07D401/04 ,  C07D211/28 ,  C07D401/06 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D417/04 ,  C07D471/04 ,  C07D473/10

    摘要： A new piperidine compound is pharmacologically effective for treatment of the arrythmia and is defined by the formula: ##STR1## in which R.sup.1 is a lower alkyl or a tolyl, R.sup.2 is hydrogen, hydroxyl, a lower alkoxy or a lower alkyl, R.sup.3 is hydrogen, a lower alkyl, a lower alkenyl, a cycloalkyl or a cycloalkylalkyl, X is --CO--, --CH.sup.2 -- or --CHOH--, g is an integer of 1 to 3, h is an integer of 1 to 3, Y is hydrogen, a lower alkyl, a lower alkenyl, cyano, CH.sup.2 COOR, R being hydrogen or a lower alkyl, a cycloalkyl, a cycloalkylalkyl, ##STR2## 1 being 1 or 2, --A--B, A being --(CH.sub.2).sub.n --, n being an integer of 1 to 5,a straight-chain alkylene group having 1 to 5 carbon atoms which is a divalent group derived from a straight-chain alkane having lower alkyl, phenyl or hydroxyl group(s) bonded directly to one or more carbon atoms constituting said alkane by removing a hydrogen atom bonded to each of the carbon atoms placed at both ends thereof,a straight-chain alkylene group having 1 to 5 carbon atoms which is a divalent group derived from a straight-chain alkene having a double bond formed between carbon atoms adjacent to each other by removing a hydrogen atom bonded to each of the carbon atoms placed at both ends thereof,--(CH.sub.2)k--S--, k being an integer of 2 to 5, --(CH.sub.2)p--CO--, p being an integer of 1 to 4, B being cyano, --NR.sub.4 R.sub.5, a heterocyclic ring or a condensed aromatic ring.

    摘要翻译： 新的哌啶化合物在治疗心律失常方面是药理学有效的，并由下式定义：其中R1是低级烷基或甲苯基，R2是氢，羟基，低级烷氧基或低级烷基，R3是氢 低级烷基，低级烯基，环烷基或环烷基烷基，X为-CO-，-CH 2 - 或-CHOH-，g为1〜3的整数，h为1〜3的整数，Y为氢 ，低级烷基，低级烯基，氰基，CH 2 COOR，R为氢或低级烷基，环烷基，环烷基烷基，A为1或2，-AB，A为 - （CH 2）n - ，n为 1至5的整数，具有1至5个碳原子的直链亚烷基，其是衍生自直接与一个或多个碳原子键合的低级烷基，苯基或羟基的直链烷烃的二价基团 通过除去与位于其两端的每个碳原子键合的氢原子构成所述烷烃，具有1至5个碳原子的直链亚烷基，其是 通过除去与位于其两端的每个碳原子键合的氢原子，通过除去彼此相邻的碳原子之间形成的双键的直链烯烃的二价基团， - （CH 2）k S - ，k为 2〜5的整数， - （CH 2）p -CO-，p为1〜4的整数，B为氰基，-NR 4 R 5，杂环或稠合芳环。

    Lactic acid derivatives and liquid crystal compositions containing the same
    7.
    发明授权
    Lactic acid derivatives and liquid crystal compositions containing the same 失效
    乳酸衍生物和含有它的液晶组合物

    公开(公告)号：US5324451A

    公开(公告)日：1994-06-28

    申请号：US870743

    申请日：1992-04-20

    申请人： Sadao Takehara ,  Tadao Shoji ,  Hiroshi Ogawa ,  Toru Fujisawa ,  Masashi Osawa

    发明人： Sadao Takehara ,  Tadao Shoji ,  Hiroshi Ogawa ,  Toru Fujisawa ,  Masashi Osawa

    IPC分类号： C07C69/773 ,  C09K19/12 ,  C09K19/20 ,  C07C69/76

    CPC分类号： C09K19/126 ,  C09K19/2021

    摘要： A compound represented by formula (I): ##STR1## wherein R.sub.1 represents an alkyl group having from 1 to 18 carbon atoms; R.sub.2 represents an alkyl group having from 2 to 16 carbon atoms; rings A, B, C, and D each represents a 1,4-phenylene group or a 1,4-phenylene group having one or two halogen atoms; Y represents a single bond, ##STR2## m and n each represents 0 or 1; p represents 0, 1, or 2; q represents 0 or an integer of from 1 to 6; and C* and C** each represents an asymmetric carbon atom in an (S)- or (R)-configuration, and a liquid crystal composition containing the compound of formula (I). The compound of formula (I) is a chiral liquid crystal compound exhibiting large spontaneous polarization, a long helical pitch, an SC* phase in a broad temperature range including room temperature, satisfactory orientation, and a high rate of response.

    摘要翻译： 由式（I）表示的化合物：其中R 1表示具有1至18个碳原子的烷基; R2表示具有2至16个碳原子的烷基; 环A，B，C和D各自表示具有一个或两个卤素原子的1,4-亚苯基或1,4-亚苯基; Y表示单键， m，n表示0或1; p表示0,1或2; q表示0或1至6的整数; 和C *和C **各自表示（S） - 或（R） - 构型中的不对称碳原子，和含有式（I）化合物的液晶组合物。 式（I）的化合物是在包括室温，令人满意的取向和高响应速度的宽温度范围内表现出大的自发极化，长螺距，SC *相的手性液晶化合物。